Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice

Cancer Chemotherapy and Pharmacology

Volumn 40, Issue 3, 1997, Pages 259-265

  Stewart, Clinton F ^a,b   Zamboni, William C ^a   Crom, William R ^a   Houghton, Peter J ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Irinotecan; Pharmacokinetics; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DRUG METABOLITE; IRINOTECAN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NEUROBLASTOMA; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BLOOD PROTEINS; CAMPTOTHECIN; FEMALE; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED CBA; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; PROTEIN BINDING;

EID: 0030917983     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050656     Document Type: Article

References (31)

1. Abigerges D, Chabot GG, Armand J, Herait P, Gouyette A, Gandia D (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every three weeks in cancer patients. J Clin Oncol 13: 210
2. Akimoto K, Kawai A, Ohya K (1994) Kinetic studies of the hydrolysis and lactonization of camptothecin and its derivatives, CPT-11 and SN-38, in aqueous solution. Chem Pharm Bull 42: 2135
3. Atsumi R, Suzuki W, Hakusui H (1991) Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 21: 1159
4. Burke TG, Munshi CB, Mi Z, Jiang Y (1995) The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J Pharm Sci 84: 518
5. Chabot GG, Gouyette A, Bissery MC (1994) Tumor influence on pharmacokinetics of the camptothecin analogue irinotecan (CPT-11) and active metabolite SN-38 in mice. Proc Am Assoc Cancer Res 35: 432
6. Creemers GJ, Lund B, Verweij J (1994) New drugs: topoisomerase I inhibitors: topotecan and ir[e]notecan. Cancer Treat Rev 20: 73
7. Curran DP (1993) The camptothecins: a reborn family of antitumor agents. J Chinese Chem Soc 40: 1
8. D'Argenio DZ, Schumitzky A (1990) ADAPT II User's Guide. Biomedical Simulations Resource, University of Southern California, Los Angeles
9. Drewinko B, Freireich EJ, Gottlieb JA (1974) Lethal activity of camptothecin sodium on human lymphoma cells. Cancer Res 34: 747
10. Gibaldi M, Perrier D (eds) (1982) Pharmacokinetics. Marcel Dekker, New York, p 409
11. Giovanella BC, Hinz HR, Kozielski AJ, Stehlin JS, Silber R, Potmesil M (1991) Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res 51: 3052
12. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54: 3723
13. Hertzberg RP, Caranfa MJ, Holdern KG, Jakas DR, Gallagher G, Mattern MG (1989) Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32: 715
14. Houghton PJ, Houghton JA, Myers L, Cheshire PJ, Howbert JJ, Grindey GB (1989) Evaluation of N-(5-indanylsulfonyl)-N′-(4-chlorophenyl) urea against xenografts of pediatric rhabdomyosarcoma. Cancer Chemother Pharmacol 25: 84
15. Houghton PJ, Chesire PJ, Myers L, Stewart CF, Synold TW, Houghton JA (1992) Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 31: 229
16. Houghton PJ, Cheshire PJ, Mallman JC, Bissery MC, Mathieu-Boue A, Houghton JA (1993) Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res 53: 2823
17. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y (1989) Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and relations to antitumor activity. Cancer Res 49: 1465
18. Kaneda N, Yokokura T (1990) Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 50: 1721
19. Kaneda N, Nagata H, Furuta T, Yokokura T (1990) Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50: 1715
20. Kunimoto T, Nitta K, Tanka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M (1987) Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47: 5944
21. McCabe FL, Johnson RL (1994) Comparative activity of oral and parenteral topotecan in murine tumor models: efficacy of oral topotecan. Cancer Invest 12: 308
22. Rivory LP, Robert J (1994) Reversed-phase high-performance liquid Chromatographic method for the simultaneous quantification of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J Chromatogr B Biomed Appl 661: 133
23. Rivory LP, Chatelut E, Canal P, Mathieu-Boue A, Robert J (1994) Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res 54: 6330
24. Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen T (1994) Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-1-(1-piperidino)-1-piperdino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54: 427
25. Sasaki Y, Hakusui Y, Mizuno S, Morita M, Miya T, Eguchi K (1995) A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite, SN-38. Jpn J Cancer Res 86: 101
26. Sasaki Y, Yoshida Y, Sudoh K, Hakusui H, Fuji H, Ohtsu T (1995) Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn J Cancer Res 86: 111
27. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH (1993) The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271
28. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y (1994) Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86: 836
29. 28a. Thompson J, Zamboni WC, Cheshire PJ, Richmond L, Luo X, Houghton JA, Stewart CF, Houthton PJ (1997) Efficacy of oral irinotecan against neuroblastoma xenografts. Anti-Cancer Drugs (in press)
30. Tsuji T, Kaneda N, Kado K, Yokokura T, Yoshimoto T, Tsuru D (1991) CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobiol Dynamics 14: 341
31. Wall ME, Wani MC (1991) Chemistry and antitumor activity of camptothecins. In: Potmesil M, Kohn KW (eds) DNA topoisomerases in cancer. Oxford University Press, New York, p 93